CNS Pharmaceuticals, Inc. (CNSP) Stock Ticker
Market factors today
Unlock the full CNSP picture
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
CNSP stock facts
| Ticker symbol | CNSP |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $7.2M |
| CEO | Rami Levin |
| Employees | 8 |
| Headquarters | Houston, TX, US |
| IPO date | 2019-11-08 |
| Website | www.cnspharma.com |
What you can see for CNSP on Tickr
Live CNSP price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CNSP report.
Rankings
FAQ
What is the ticker symbol for CNS Pharmaceuticals, Inc.?
The ticker symbol for CNS Pharmaceuticals, Inc. is CNSP, listed on the NASDAQ Capital Market.
What is CNSP?
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of…